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INTRODUCTION
Polymyositis (PM) and dermatomyositis (DM) are the two
most common idiopathic inflammatory myopathies. They
have in common the presence of moderate to severe muscle
weakness and inflammation in the muscle, and the diagnosis
is based on combination of clinical examination, electromyo-
graphic data, serum muscle enzyme levels, and muscle biop-
sy findings (1). In muscle biopsy, they are histopathological-
ly characterized by the presence of mononuclear cellular infil-
trates in skeletal muscle tissue. Previous studies also have
revealed a significant difference in the pathogenesis of inflam-
matory myopathies, such as a complement-mediated injury
directed against the intramuscular microvasculature in DM
or T-cell-mediated cytotoxicity against major histocompati-
bility complex (MHC) class I expressing muscle fibers in PM,
showing distinctive differences in the types and patterns of
infiltrating mononuclear cells (2, 3). In some subsets of pa-
tients with PM or DM, however, muscle biopsy may fail to
show any significant inflammatory reactions, and may even
appear completely normal. 
On the other hand, inflammatory cell infiltration could
be a prominent feature in dysferlinopathy, a group of mus-
cular dystrophies inherited as an autosomal recessive trait (4).
Dysferlinopathy is caused by a mutation in DYSF and pro-
duces the deficiency of dysferlin in the sarcolemma as demon-
strated by immunocytochemistry (5, 6). There are two im-
portant allelic diseases in dysferlinopathy-one with predom-
inant proximal limb muscle weakness (limb-girdle muscu-
lar dystrophy type 2B [LGMD2B], MIM, #253601), and the
other with prominent distal leg muscle weakness (Miyoshi
myopathy [MM], MIM #254130) (4). Despite the distinct
patterns of muscle involvement, they have many features in
common such as very high serum CK level and onset in late
teens. When muscle biopsy from patients with dysferlinopa-
thy shows prominent inflammatory changes, an incorrect diag-
nosis of an inflammatory myopathy can be made, and can
leads to inappropriate treatment and care in clinical practice.
Recently, the immunohistochemical stains have been used
to make up the limitation of conventional light microscopy
in the differential diagnosis of inflammatory myopathies and
muscular dystrophies with inflammatory changes. It also ena-
bles us to analyze infiltrating mononuclear cells and identify
immunological markers, such as MHC class I or membrane
attack complex (MAC). 
The present study has been designed to characterize the
types and patterns of the infiltrating mononuclear cells and
the expression profiles of MHC class I and MAC in patients
with idiopathic inflammatory myopathies (PM and DM) and
dysferlinopathy with inflammatory cell infiltration. 
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Differential Immunohistological Features of Inflammatory Myopathies
and Dysferlinopathy
This study was performed in order to characterize the types of the infiltrating cells,
and the expression profiles of major histocompatibility complex (MHC) class I and
membrane attack complex (MAC) in patients with inflammatory myopathies and
dysferlinopathy. Immunohistochemical stains were performed using monoclonal
antibodies against several inflammatory cell types, MHC class I, and MAC in mus-
cles from inflammatory myopathies and dysferlinopathy. There was significant dif-
ference in the types of infiltrating cells between polymyositis (PM), dermatomyosi-
tis (DM), and dysferlinopathy, including significantly high CD4+/CD8+ T cell ratio
and B/T cell ratio in DM. In dysferlinopathy, CD4+ T cells were the most abundant
and the proportions of infiltrating cell types were similar to those of DM. MHC class
I was expressed in muscle fibers of PM and DM regardless of the presence of inflam-
matory infiltrates. MAC was expressed in necrotic fibers and vessels of PM and DM.
One patient with early stage DM had a MAC deposits on endomysial capillaries. In
dysferlinopathy, MAC deposit was also observed on the sarcolemma of nonnecrotic
fibers. The analysis of inflammatory cells, MHC class I expressions and MAC deposits
may help to differentiate dysferlinopathy from idiopathic inflammatory myopathy. 
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Complement Membrane Attack Complex
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MATERIALS AND METHODS
Patients
Between 2004 and 2006, we had muscle biopsies from 32
patients with idiopathic inflammatory myopathies and four
patients with dysferlinopathy (one patient with LGMD2B
and three with MM). Among patients with inflammatory
myopathies, 13 patients (nine patients with PM and four
with DM) were finally selected for the analysis according to
the following inclusion criteria: 1) A detailed clinical record
should be available, 2) clinical and laboratory findings should
fulfill the Bohan and Peter’s diagnostic criteria of PM and
DM (1), 3) immune modulating therapy showed definite
clinical improvement, 4) enough amount of frozen muscle
specimen is available for the immunohistochemical study,
and 5) normal dysferlin expression in muscle biopsy. 
The diagnosis of dysferlinopathy was confirmed by the
selective loss of dysferlin in immunohistochemical stain using
anti-dysferlin antibodies (Clone Ham1/7B6, Novocastra Lab-
oratories Ltd, Newcastle upon Tyne, U.K.). The detailed
methods of dysferlin immunohistochemistry had been des-
cribed previously (7). 
Then, we have divided our patients into four groups on
the basis of clinical and pathological features. Patient’s clini-
cal data are summarized in Table 1. Also, five normal mus-
cle specimens were obtained from patients undergoing ortho-
pedic operations with written informed consents, and served
as controls for immunohistochemical studies.
Group 1: Polymyositis with typical inflammatory cell 
infiltration 
The first group consisted of five patients fulfilling both clin-
PM, polymyositis; DM, dermatomyositis; mo, months; AZA, azathioprine; IVIG, intravenous immunoglobulin; MTX, methotrexate; FANA, fluorescent anti-
nuclear antibody.
Pati-  
ents
Sex/
age
(yr)
Muscle symptoms CK level
Associated 
autoantibodies
Treatment Duration Pathological feature
Group 1: PM with typical inflammatory cell infiltrations
1 F/64 Weakness (distal) 12 mo Infiltration, degeneration, regeneration 1,544 (-) Steroid, AZA
2 M/61 Weakness 3 mo Infiltration, degeneration, regeneration 11,070 FANA 1:80,   Steroid, AZA 
Anti-Jo-1 (+), Anti-Ro (+)
3 M/67 Weakness 5 yr Infiltration, degeneration, regeneration, atrophy 1,005 (-) Steroid
4 F/51 Weakness 5 mo Infiltration, degeneration, regeneration, atrophy 9,953 (-) Steroid, AZA
5 F/48 Weakness, arthralgia 12 mo Infiltration, degeneration, regeneration, atrophy 1,123 (-) Steroid, AZA
Group 2: PM without definite inflammatory cell infiltrations
6 F/59 Weakness 3 mo Degeneration, atrophy, no infiltration 6,208 FANA 1:320,  IVIG, Steroid, 
Anti-Ro (+) MTX
7 M/70 Weakness 2 mo Atrophy, no infiltration 8,615 (-) Steroid, IVIG
8 M/37 Weakness, dyspnea 3 mo Degeneration, no infiltration 2,815 Anti-Jo-1 (+), Anti-La (+) Steroid
9 F/61 Weakness 4 mo Degeneration, atrophy, no infiltration 3,178 (-) Steroid
Group 3: DM with typical pathological features
10 F/6 Weakness, dysphagia,  3 mo Infiltration, perifascicular atrophy 1,057 (-) Steroid
heliotrope
11 M/73 Weakness, Gottron’s  12 mo Infiltration, perifascicular atrophy 2,700 (-) Steroid
papule, facial rash
12 F/44 Myalgia, facial rash 8 mo Infiltration, perifascicular atrophy, degeneration,  271 (-) Steroid
regeneration
13 M/57 Weakness, dysphagia,  5 mo Infiltration, perifascicular atrophy, degeneration,  4,767 FANA 1:1,280 Steroid
heliotrope regeneration
Group 4: Dysferlinopathy 
14 M/28 Lower leg weakness 10 yr Infiltration, degeneration, regeneration,  16,550 (-) No treatment
hypertrophy, atrophy
15 M/28 Lower leg weakness 7 yr Infiltration, degeneration, regeneration,  9,301 (-) No treatment
hypertrophy, atrophy
16 M/19 Lower leg weakness 3 yr Degeneration, regeneration, hypertrophy,  14,847 (-) No treatment
atrophy
17 F/30 Proximal limb weakness 2 yr Degeneration, regeneration, hypertrophy,  8,281 (-) No treatment
atrophy
Table 1. Clinical and laboratory information of the patientsImmonohistochemical Findings of Inflammatory Myopathy and Dysferlinopathy 1017
ical and histopathological features according to Bohan and
Peter’s criteria. All had a symmetrical weakness of proximal
limbs, except for one who initially presented with an initial
muscle weakness of bilateral forearms and hands, which even-
tually progressed to limb-girdle and neck flexor muscles (pa-
tient 1). Symptom duration varied between 3 to 12 months
except for one who had a five year history of progressive prox-
imal muscle weakness (patient 3). Histopathologically, all
patients showed clear inflammatory cell infiltrates as well as
necrosis and regeneration of muscle fibers in their muscle tis-
sues. They all had an elevated CK level and active myopath-
ic patterns on needle electromyography. Immunosuppressive
therapy was performed in all, either with prednisolone only
or in combination with azathioprine. All of them showed
clinical improvement after treatment.
Group 2: Polymyositis without inflammatory cell infiltration
The second group consisted of four patients with definite
clinical features of myositis, but without detectable infiltra-
tion of inflammatory cells in their muscle biopsies. They all
presented with a progressive and symmetrical weakness of
proximal limbs, and showed an elevated CK level and active
myopathic features on electromyography. Despite clinical symp-
toms and laboratory findings of myositis, the histopathologi-
cal evaluation of the muscle biopsies did not reveal inflam-
matory infiltrates typical of myositis, and there were only non-
specific myopathic findings, such as atrophy, necrosis or regen-
eration of muscle fibers in their muscle biopsies. Symptom
duration varied between 2 to 4 months with a median dura-
tion of 3 months. One patient was found to have an advanced
gastric cancer at the time of the diagnosis (patient 7). Two
patients received immunosuppressive therapy with predniso-
lone and intravenous immunoglobulin therapy (patient 6, 7).
The others were treated with prednisolone alone (patients 8, 9).
All the patients in this group also responded to the treatment.
Group 3: Dermatomyositis with typical pathological 
features
This group consisted of four patients with dermatomyosi-
tis according to Bohan and Peter’s criteria. Three patients
fulfilled the criteria for definite myositis. One patient (patient
12) presented with myalgia rather than weakness in limbs,
and serum CK level was normal. However, she had a lilac
discolorization of the eyelids (heliotrope) with periorbital
edema and facial rash, and fulfilled the criteria of electromyo-
graphic study and histopathological findings for myositis,
and was diagnosed as probable dermatomyositis based on
Bohan and Peter criteria. Histopathologically, all patients
had characteristic findings of dermatomyositis, such as peri-
fascicular atrophy and inflammatory infiltrations in perimy-
sium or perivascular region. One patient (patient 10) was a
6-yr-old girl with a shorter duration of symptoms than the
others. All patients received immunosuppressive therapy with
prednisolone alone, and showed a clinical improvement.
Group 4: Dysferlinopathies
This group consisted of three patients with MM and one
with LGMD2B. All of them were previously diagnosed as
dysferlinopathy on the basis of a selective deficiency of dys-
ferlin in their muscle biopsies. Three patients (patients 14,
15, 16) were compatible with a phenotype of MM with high
CK levels and predominant distal lower leg weakness which
had been progressive worse over years. The patient 15 had
been erroneously diagnosed and treated as PM on the basis
of routine histochemistry findings of muscle biopsy at another
hospital. Another patient (patient 17) was a 21-yr-old female
with progressive proximal limb muscle weakness for two years
with high serum CK level. Among four patients with dys-
ferlinopathy, two (patient 15 and 16) showed an inflamma-
tory change in their muscle biopsies. 
Immunohistochemistry
All muscle specimens were obtained by diagnostic muscle
biopsy which had been performed before the treatment, and
were frozen and stored at -70℃ until used. For immunohis-
tochemical analyses, serial 7 μ m cryostat sections were cut
and mounted on gelatin-coated glass slides at -20℃, and air-
dried for 30 min at room temperature. The first and the last
sections were stained with hematoxylin and eosin in order to
confirm that the configuration of the sections were unchanged
throughout the serial sections collected for immunohistochem-
istry. Sections were fixed in acetone for 5 min and then rinsed
in phosphate buffered saline (PBS). Endogenous peroxidase
was blocked with 3% H2O2 for 10 min. After rinsed by PBS
for 10 min, sections were incubated for 60 min with primary
antibodies. Mouse monoclonal antibodies were all purchased
from Dako (Glostrup, Denmark) (Table 2), and were used to
identify CD8+ T cells, CD4+ T cells, B cells (CD20), mac-
rophages (CD68), MHC class I (HLA-ABC) and C5b-9 com-
plement deposits (membrane attack complex, MAC). After
washing the specimens with PBS for 5 min three times, the
secondary antibodies coupled with peroxidase molecules were
Marker for Antibody Dilution Clone
CD8 T lymphocyte Anti-CD8 1:50-1:100 C8/144B
CD4 T lymphocyte Anti-CD4 1:50-1:100 MT310
B lymphocyte Anti-CD20 1:200-1:400 L26
Macrophage Anti-CD68 1:50-1:100 EBM11
MHC class I Anti-HLA-A/B/C 1:50-1:100 W6/32
C5b-9 (MAC) Anti-C5b-9 1:25-1:50 aE11
MHC, major histocompatibility complex; MAC, membrane attack com-
plex.
Table 2. Antibody panel for immunohistochemistry1018 J.-H. Choi, Y.-E. Park, S.-I. Kim, et al.
applied for 30 min. Subsequently, it was incubated with a
chromogenic substrate solution for peroxidase 3,3′ -diami-
nobenzidine tetrahydrochloride (DAB) (Rabbit/Mouse Ig
Immunohistochemistry Kit, EnVisionTM+Detection System,
DAKO, Glostrup, Denmark). After a final rinse, the sections
were counterstained with hematoxylin and mounted. 
Evaluation of staining
For quantitation of inflammatory infiltrates, CD8+ and
CD4+T cells, B cells and macrophages were counted in seri-
al sections under the light microscope. Two different clusters
were chosen for each patient and the number of cells in each
cell type was manually counted. The clusters were random-
ly selected from the groups of cells surrounding or invading
muscle fibers under×100 magnification, and the results of
counting were compared with those in each group (Group
1, 3, 4). MHC class I and MAC were assessed as to the dis-
tribution and intensity of the staining. 
RESULTS
Phenotypic characteristics of inflammatory cells
As shown in Table 3, in the patients with PM (group 1), ab-
undant CD8+ T cells and macrophages were observed, acco-
unting for 36.6±12.7% and 32.0±15.2% of the total cells
counted, respectively. They were mainly observed as clusters
or scattered in endomysial spaces, but were also found in per-
PM (group 1) Cells DM (group 3) MD (group 4)
Macrophage (%) 32.0±15.2 36.9±9.1 29.3±10.4 
T cell (%) 62.2±15.3 48.9±9.2 61.2±6.1 
CD4/Total (%) 25.6±7.0*,� 36.6±12.3 42.2±7.7 
CD8/Total (%) 36.6±12.7*,� 12.3±8.6 19.0±7.9
CD4/CD8 ratio 0.805±0.385*,� 4.800±4.110 2.791±1.723
CD4/T cell (%) 42.4±11.2*,� 75.2±14.6 69.2±12.0
CD8/T cell (%) 57.6±11.2*,� 24.8±14.6 30.8±12.0
B cell (%) 5.9±2.8* 14.3±9.8 9.6±5.6 
B cell/T cell ratio 0.099±0.057* 0.318±0.226 0.153±0.078
Table 3. Quantitative analysis of inflammatory cells 
Values are expressed as mean±SD. 
*P<0.05 vs. group 3 (DM); 
� P<0.05 vs. group 4 (MD).
PM, polymyositis; DM, dermatomyositis; MD, muscular dysferlinopathy.
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PM
H&E CD8 CD4 CD20 CD68
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DF
100 μ m
Fig. 1. Cellular composition of inflammatory infiltrates in polymyositis (patient 3, A-E), dermatomyositis (patient 10, F-J), and dysferlinopa-
thy (patient 15, K-O). In polymyositis (PM), the inflammatory infiltrates are mainly observed in endomysial spaces, and CD8+ T cells are
most abundant. In dermatomyositis (DM), there are two inflammatory infiltrates in perivascular areas. CD4+ T cells and macrophages are
more frequent than others. In dysferlinopathy (DF), there are inflammatory infiltrates in perivascular areas. CD4+ T cells and macrophages
are mainly observed as in DM. A few CD8+ T cell are also scattered in endomysial spaces, but they do not surround or invade a normal-
appearing muscle fibers.
H&E, hematoxylin and eosin stain; CD8, immunostaining for CD8+ T cells; CD4, immunostaining for CD4+ T cells; CD20, immunostain-
ing for B cells; CD68, immunostaining for macrophages. Immonohistochemical Findings of Inflammatory Myopathy and Dysferlinopathy 1019
imysial and perivascular sites. CD4+T cells were less abdun-
dant, accounting for 25.6±6.6% and were detected mainly
in perimysial or perivascular sites (Fig. 1A-E). The most inter-
esting finding was that a number of non-necrotic fibers were
focally surrounded and invaded by predominantly CD8+ T
cells (Fig. 1B). On the other hand, necrotic fibers were invaded
by CD4+ T cells and macrophages as well as CD8+ T cells.
Only a few B cells were detectable mainly in perivascular sites. 
In the patients with DM (group 3), inflammatory cells were
mainly found in perimysial and perivascular sites, and CD4+
T cells and macrophages were more frequent, accounting for
36.6±9.4% and 36.9±9.1% of the total, respectively. B
cells were more abundant than in PM patients (Fig. 1F-J). In
addition, there were significant differences in CD4+/CD8+
T cell ratio and B/T cell ratio between PM and DM (0.8±
0.4% vs. 4.8±4.1%; P=0.001, and 0.10±0.06% vs. 0.32
±0.23%; P=0.009). 
In the patients with dysferlinopathy (group 4, patient 15
and 16), the types and patterns of the inflammatory cells were
similar to those of DM patients (group 2), such as the high
CD4+/CD8+T cell ratio and the high percentage of B cells.
CD4+ T cells were most abundant, accounting for 42.2±
7.7% of the total, and were mainly observed in perivascular
sites (Fig. 1K-O). 
Expression of MHC class I and MAC
The MHC class I reactivity was clearly expressed on nor-
mal-looking fibers as well as degenerating fibers in PM (Fig.
2B-D) and DM (Fig. 2G, H) patients with prominent inflam-
matory cellular infiltrates. The non-necrotic fibers showed a
marked sarcolemmal reactivity for MHC class I. In some pa-
tients, pronounced cytoplasmic staining was present in non-
necrotic fibers as well as necrotic ones. In addition, MHC
class I was strongly expressed in the extracellular matrix, en-
dothelial cells of capillaries, arterioles and venules. There was
no significant difference in MHC class I expression between
PM and DM patients. However, the perifascicular areas tend-
ed to be strongly stained with cytoplasmic reactivity in DM
patients. Interestingly, the expression of MHC class I was also
up-regulated in normal-looking fibers in the patients with
PM without inflammatory infiltrates (Fig. 2E, F). In this
group of the patients, a varying pattern and intensity of the
staining was observed; MHC class I expression was restrict-
ed to the sarcolemma in three patients whereas it was also
observed within their cytoplasm in one patient (patient 6).
In the patients with dysferlinopathy, there was no or only mild
expression of MHC class I on the sarcolemma (Fig. 2I, L). 
MAC deposits were found within necrotic fibers and ves-
sel walls in both PM and DM patients (Fig. 3A, B). Especial-
ly, in a 6-yr-old girl with DM who had a disease duration of
three months (patient 10), there were MAC deposits on en-
domysial capillaries as well (Fig. 4A, B). In other patients with
DM, by contrast, no endomysial MAC deposit was observed
(Fig. 4C, D). In the patients with dysferlinopathy, MAC de-
posits were detected in necrotic fibers and vessel walls, too.
A B C D
E F G H
I J K L
100 μ m
Fig. 2. Immunohistochemical localization of MHC class I in control, polymyositis, dermatomyositis, and dysferlinopathy. In control muscle
(A), MHC class I reactivity is present on the endothelium, but staining of the sarcolemma is negative. In polymyositis (B-F) and dermato-
myositis (G, H), the non-necrotic muscle fibers show marked sarcolemmal reactivity for MHC class I. In some patients with prominent inflam-
matory infiltrates (B, D), pronounced cytoplasmic staining is present in non-necrotic fiber as well as in necrotic fibers. In patients with dys-
ferlinopathy (I-L), MHC class I is expressed in the extracellular matrix and endothelium, but not on the sarcolemma of muscle fibers.   1020 J.-H. Choi, Y.-E. Park, S.-I. Kim, et al.
Interestingly, three of the four dysferlinopathy patients (pati-
ent 14, 16, 17) had sarcolemmal MAC deposits on nonnecrot-
ic fibers, especially in the perimysial or perivascular spaces
(Fig. 3C, D). However, sarcolemmal MAC deposits on non-
necrotic fibers were not present in patients with inflamma-
tory myopathy. 
DISCUSSION
The idiopathic inflammatory myopathies are autoimmune-
mediated disorders, which is supported by their association
with other autoimmune disorders, autoantibodies, and the
evidence of T cell-mediated myocyotoxicity or complement-
mediated microangiopathy (2, 3, 8). They are histologically
characterized by the mononuclear cellular infiltrates in skele-
tal muscle tissue. However, the types and patterns of cellular
infiltrates are distinct, probably due to the significant differ-
ences in autoimmune pathogenesis. This study again demon-
strated differences in cell types and distributions of cellular
infiltrates, and patterns of inflammation between PM and
DM as previously studied (9-12). In PM, the inflammatory
cells were found mainly in endomysial sites, and CD8+ T
cells (cytotoxic) were most abundant and focally surrounded
and invaded non-necrotic fibers expressing MHC class I anti-
gen. These findings suggest that cytotoxic T-cell-mediated
muscle fiber injuries occur through immune-mediated pro-
cess. In DM, the inflammatory cells were predominantly found
in perivascular and perimysial sites, and to a lesser extent, in
endomysial site. In addition, they were mainly consisted of
CD4+ T cells and B cells, suggesting a humorally mediat-
ed process. 
Interestingly, inflammatory changes are frequent in muscle
of patients with dysferlinopathies (4, 13), and similar inflam-
matory features have been found in SJL/J mice with DYSF
mutation which also results in a lack of sarcolemmal dysfer-
lin (14). Thus, when dysferlinopathy is associated with inflam-
matory infiltrates, it can not be easily distinguished from in-
flammatory myopathy by routine histochemistry. Under im-
munohistochemical studies, however, the types and patterns
of inflammation seem to differ from that observed in inflam-
matory myopathies. In our study, inflammatory cells were
mainly observed in perivascular sites, and CD4+T cells were
most abundant in patients with dysferlinopathy. Furthermore,
A B
C D
100 μ m 100 μ m
100 μ m 200 μ m
Fig. 3. Immunohistochemical localization of MAC depositis. In PM (A) and DM (B), there are MAC depositis on vessel walls of arteriole and
within necrotic muscle fibers. In dysferlinopathy  (C, D), MAC deposits are found on the sarcolemma of nonnecrotic fibers as well as on
vessel walls. Immonohistochemical Findings of Inflammatory Myopathy and Dysferlinopathy 1021
CD8+T cells were scarce and there was no non-necrotic fibers
surrounded or invaded by CD8+T cells. These findings indi-
cate the cytotoxic T-cell-mediated immune mechanism direct-
ed against muscle fibers is unlikely in dysferlinopathy. In our
study, dysferlinopathy shared several features with DM in
terms of the types of inflammatory cellular infiltrates, includ-
ing high CD4+/CD8+ T cell ratio and the high percent-
age of B cells. However, the expression of MHC class I and
MAC deposits were significantly different in DM and dys-
ferlinopathy, suggesting the inflammatory reactions in dys-
ferlinopathy are not related with a specific immune mecha-
nism as is seen in DM, although the origin and role of these
inflammatory reactions remain unclear in dysferlinopathy. 
In normal muscle fibers, MHC class I is not expressed on
the sarcolemma. The abnormal expression of MHC class I
always occurs in muscle biopsies from idiopathic inflamma-
tory myopathies. An increased expression of MHC class I was
observed in patients with chronic, inactive inflammatory myo-
pathies as well as with active inflammatory myopathies (15-
18). In addition, MHC class I is detectable even after the im-
munosuppressive treatment has been initiated (19). These
findings suggest that the expression of MHC class I plays an
important role in the pathogenesis of idiopathic inflamma-
tory myopathies. In our study, a diffuse expression of MHC
class I was observed in patients with idiopathic inflammato-
ry myopathies as previously reported. It is interesting that
the expression of MHC class I was not only observed in PM
patients with active inflammatory infiltrates, but also in those
without definite inflammatory infiltrates in their muscle biop-
sies. Their mean duration of disease after onset of symptom
was 3 months, which is clearly shorter than that of our PM
patients with prominent inflammatory infiltrates. Therefore,
the expression of MHC class I might play a central role in
mediating muscle weakness at the early stage of inflamma-
tory myopathies, although further study will be needed in
order to verify this assumption.
While it is widely accepted that MHC class I expression
is up-regulated in inflammatory myopathies, it is not clear
whether it is a result of the nonspecific response to muscle
degeneration/regeneration or of the specific disease process
itself. Previous reports have shown that MHC class I is induced
by proinflammatory cytokines such as IFN-γand TNF-α(20,
21), which are highly expressed in inflammatory myopathies.
IL-1αalso induces the expression of MHC class I on myotubes
A B
C D
100 μ m 100 μ m
100 μ m 100 μ m
Fig. 4. In a patient with early stage DM (patient 10), MAC deposits are clearly observed on endomysial capillaries (A, B, arrows). In a patient
with late stage DM (patient 12), there is no MAC deposit on capillaries (C, D, arrows). 1022 J.-H. Choi, Y.-E. Park, S.-I. Kim, et al.
in vitro (22). Interestingly, the distribution of capillaries pos-
itive for IL-1α , and muscle fibers positive for MHC class I is
identical in both chronic PM and DM patients (17). Recent-
ly, however, it had been hypothesized that the up-regulation
of MHC class I is an initial event because a transgenic mice
with conditionally up-regulated MHC class I has been led
to self-sustained autoimmune myositis (22). It is supported
by several studies that muscle fibers in inflammatory myo-
pathies express MHC class I as well as class II independently
of the inflammatory infiltrates, as was also observed in our
study (23, 24). 
In two patients with dysferlinopathy, there was no or only
mild expression of MHC class I on the sarcolemma in spite
of the inflammatory infiltrates. There had been one previous
study which demonstrated the expression of MHC class I on
the sacolemma of non-necrotic muscle fibers in dysferlinopa-
thy with inflammation (25). However, the up-regulation of
MHC class I was not accompanied by T-cell cytotoxicity,
which is similar to the result of our study. In addition, knock-
ing out the MHC class I gene in SJL/J mice does not alter
the extent of myopathy, showing that it is not required for
the development of myopathy (26). These findings indicate
that MHC expression is not an essential feature in the patho-
genesis of dysferlinopathy. 
In dermatomyositis, the primary antigenic target is the
endothelium of the endomysial capillaries. After the activa-
tion of complement, C5b-9 MAC is deposited on capillaries,
which sequentially induce capillary necrosis, perivascular
inflammation, ischemia, and destruction of muscle fibers (2,
8). However, no significant difference in MAC deposits bet-
ween PM and DM was observed in this study. In addition,
no MAC deposit on endomysial capillaries was seen in DM
patients except for a girl with a shorter duration of the dis-
ease (patient 10). This might be explained by that the com-
plement-mediated microvasculopathy is a primary pathogenic
event only at the early stage of disease (27, 28). A recent study
also showed that MAC deposits on capillaries were observed
from patients who were within 1 to 3 months from the onset
of childhood DM (29). These findings suggest that MAC
deposits on endomysial capillaries could be a useful indica-
tor for the diagnosis of DM at an early stage. 
In three patients with dysferlinopathy, MAC deposits were
also detected on sarcolemma of nonnecrotic fibers. This find-
ing is not likely to be associated with inflammatory reactions
because only one of them had inflammatory infiltrates and
none of the patients with inflammatory myopathy had sar-
colemmal MAC deposits. Although sarcolemmal MAC de-
posits on nonnecrotic fibers have been observed in some types
of muscular dystrophy, the pathogenetic significance remains
unclear. A recent study also failed to demonstrate the pres-
ence of sarcolemmal IgG or IgM that would be required to
initiate the classic complement pathway, and C3 deposits that
would be required to propagate the alternative pathway (30).
However, the presence of sarcolemmal MAC deposits on non-
necrotic fibers may help to distinguish between a dysferlinopa-
thy and an idiopathic inflammatory myopathy histologially. 
Recently, it has been recognized that the clinical criteria
of Bohan and Peter cannot exactly distinguish PM from inclu-
sion body myositis (IBM) or certain muscular dystrophies
(2, 3, 8). Thus, some patients with IBM or muscular dystro-
phies with inflammatory changes can be misdiagnosed and
treated as PM, being exposed to the long-term side-effects
of steroid and immunosuppressants. On the other hand, some
patients with PM who fulfill the clinical criteria but with-
out inflammatory reactions in muscle biopsy could be faced
to a diagnostic dilemma. With the recent advances in the
immunopathogenesis of inflammatory myopathies demon-
strated by various immunohistochemical studies, the new
diagnostic criteria were recently introduced, in which the
MHC/CD8 complex is considered as a specific immunolog-
ical marker (2, 8). In this study, all of our patients with PM
fulfilled the Bohan and Peter’s criteria irrespective of the pres-
ence of inflammatory reactions in their muscle biopsies. All
showed a marked sarcolemmal reactivity for MHC class I with
or without CD8+ T cells, strongly supporting the impor-
tance of MHC/CD8 complex in the pathological diagnosis
of PM.
In conclusion, although the inflammatory cell infiltrates
can be observed in dysferlinopathy as well as in idiopathic
inflammatory myopathies (PM and DM), there are signifi-
cant differences in the types and patterns of infiltrating cells
as seen in our study. The differences in the patterns of MHC
class I expression and MAC deposits may also help to distin-
guish dysferlinopathy with inflammatory reactions and idio-
pathic inflammatory myopathy. 
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